Avita Medical rises on skin disorder treatment trial success

AVITA Medical

12/09/2022 22:56

** Avita Medical's shares  RCEL.O  up 5.8% at $6.56 in
after-market trade
    ** Shares rise after co's vitiligo treatment met key goal in
a controlled trial  urn:newsml:reuters.com:*:nGNX6w5pMK
    ** 36% of co's treatments resulted in repigmentation of at
least 80% of the treated area, meeting primary endpoint of the
study
    ** AVITA Medical continues to plan for submission to FDA by
the end of 2022
    ** Up to last close, stock fell 46.5% YTD

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((Nandhini.srinivasan@thomsonreuters.com))